Every 10-Q that Tectonic Therapeutic, Inc. (TECX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TECX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TECX filings page.
Tectonic Therapeutic, Inc., a clinical-stage biotech focused on GPCR-targeted biologics using its GEODe™ platform, reported net losses of $22.3 million and $47.5 million for the three and six months ended June 30, 2026. Operating expenses were driven by research and development of TX45 and TX2100 and expanding general and administrative infrastructure; the company has not yet generated product revenue.
Cash and cash equivalents were $227.1 million as of June 30, 2026, with an accumulated deficit of $270.3 million. Tectonic raised additional capital by selling 432,306 shares through its at the market offering for gross proceeds of $13.4 million and net proceeds of $13.1 million. Management believes existing cash will fund operations for at least 12 months.
Clinically, the TX45 APEX Phase 2 trial in PH-HFpEF completed enrollment of 191 patients across 14 countries, about 72% with baseline pulmonary vascular resistance above 3 WU; an independent monitoring committee recommended continuation without modification, and topline data are expected early in the first quarter of 2027. A separate Phase 2 trial in PH-ILD started in March 2026. TX2100 for hereditary hemorrhagic telangiectasia is in an ongoing Phase 1a healthy volunteer study, with six single-dose cohorts dosed and topline results expected by the end of the third quarter of 2026.
Tectonic Therapeutic, Inc. reported a larger quarterly loss as it ramped up clinical development. For the three months ended March 31, 2026, net loss was $25.2 million compared with $15.9 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $20.9 million from $13.0 million, largely from CRO and CDMO costs for TX45 Phase 2 trials and a bigger R&D team. General and administrative expenses increased to $6.4 million from $5.3 million, reflecting higher stock-based compensation and staffing.
The company ended the quarter with $236.9 million in cash and cash equivalents and used $18.4 million in operating cash flow. Management believes this cash will fund operations for at least 12 months. Tectonic advanced its pipeline, including the APEX Phase 2 trial of TX45 in PH-HFpEF, a new Phase 2 trial in PH-ILD, and a Phase 1a healthy volunteer trial of TX2100 for HHT.
Tectonic Therapeutic (TECX) reported Q3 2025 results, highlighting continued R&D investment and a solid balance sheet. Net loss was $19.0 million (basic and diluted EPS $(1.02)) on operating expenses of $21.9 million, including R&D $16.9 million and G&A $5.0 million. Interest income was $2.9 million.
Cash and cash equivalents were $268.4 million as of September 30, 2025, and stockholders’ equity was $267.5 million. The company closed a February 2025 private placement for net proceeds of $173.1 million. Management believes current cash will fund planned operations for at least 12 months from the financial statements’ issuance date.
Pipeline updates: TX45 advanced with positive Phase 1b hemodynamic data in PH-HFpEF and PH-HFrEF, and the 24‑week, placebo‑controlled APEX Phase 2 trial (SC dosing) is ongoing with topline results expected in 2026. TX2100 completed IND‑enabling NHP GLP tox in 2025, with a Phase 1 in healthy volunteers planned for early 2026.